

HR 6973

Enhanced Access to Affordable Medicines Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 8, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 9, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/6973>

Sponsor

Name: Rep. Carter, Earl L. "Buddy" [R-GA-1]

Party: Republican • **State:** GA • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Craig, Angie [D-MN-2]	D · MN		Apr 26, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 9, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 4351	Related bill	Jun 6, 2022: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Mar 8, 2022)

Enhanced Access to Affordable Medicines Act of 2022

This bill specifies that the Food and Drug Administration may approve generic drugs with different labels than the brand-name versions if, among other requirements, the brand-name drug is subject to an active patent or exclusivity period and a revised label for the brand-name drug is approved within 90 days (rather than 60 days) of the expiration of the patent or exclusivity period.

Actions Timeline

- Mar 9, 2022: Referred to the Subcommittee on Health.
- Mar 8, 2022: Introduced in House
- Mar 8, 2022: Referred to the House Committee on Energy and Commerce.